Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 12.15 AUD 0.33% Market Closed
Market Cap: 608.2m AUD
Have any thoughts about
Clinuvel Pharmaceuticals Ltd?
Write Note

Clinuvel Pharmaceuticals Ltd
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Clinuvel Pharmaceuticals Ltd
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Other Current Assets
AU$1.3m
CAGR 3-Years
15%
CAGR 5-Years
18%
CAGR 10-Years
5%
Immutep Ltd
ASX:IMM
Other Current Assets
AU$1.9m
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
6%
Mesoblast Ltd
ASX:MSB
Other Current Assets
$20.5m
CAGR 3-Years
43%
CAGR 5-Years
19%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Other Current Assets
$126m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Other Current Assets
AU$31.9m
CAGR 3-Years
234%
CAGR 5-Years
100%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Other Current Assets
AU$744k
CAGR 3-Years
100%
CAGR 5-Years
95%
CAGR 10-Years
N/A
No Stocks Found

Clinuvel Pharmaceuticals Ltd
Glance View

Market Cap
608.4m AUD
Industry
Biotechnology

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.

CUV Intrinsic Value
20.89 AUD
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Clinuvel Pharmaceuticals Ltd's Other Current Assets?
Other Current Assets
1.3m AUD

Based on the financial report for Jun 30, 2024, Clinuvel Pharmaceuticals Ltd's Other Current Assets amounts to 1.3m AUD.

What is Clinuvel Pharmaceuticals Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
5%

Over the last year, the Other Current Assets growth was 24%. The average annual Other Current Assets growth rates for Clinuvel Pharmaceuticals Ltd have been 15% over the past three years , 18% over the past five years , and 5% over the past ten years .

Back to Top